POLY MEDICURE LTD. - 531768 - Board recommends Dividend
Poly Medicure Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 24, 2022, inter alia, has recommended Dividend of Rs. 2.5 (Two and half Rupees) per Equity Shares (50%) of Rs. 5 each for the Financial Year 2021-22, subject to the approval of shareholders. POLY MEDICURE LTD. - 531768 - Financial Results For The Year Ended 31St March, 2022.
Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 24th May, 2022, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Audited Financial Results (Consolidate & Standalone) for the year ended on 31st March 2022. b) Recommendation of Dividend of Rs. 2.5 (Two and half Rupees) per Equity Shares (50%) of Rs. 5 each for the Financial Year 2021-22, subject to the approval of shareholders. POLY MEDICURE LTD. - 531768 - Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Dated 24 May, 2022.
Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 24th May, 2022, at 232-B, 3RD Floor, Okhla Industrial Estate, Phase-III, New Delhi - 110020, approved the following businesses: a) Audited Financial Results (Consolidate & Standalone) for the year ended on 31st March 2022. b) Recommendation of Dividend of Rs. 2.5 (Two and half Rupees) per Equity Shares (50%) of Rs. 5 each for the Financial Year 2021-22, subject to the approval of shareholders. POLY MEDICURE LTD. - 531768 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company POLY MEDICURE LTD. 2 CIN NO. L40300DL1995PLC066923 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2021-22, 2022-23 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* NIL Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-22, 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-AVINASH CHANDRADesignation :-COMPANY SECRETARY AND COMPLIANCE OFFICER Name of the Chief Financial Officer :- NARESH VIJAYVERGIYA Designation : -CHIEF FINANCIAL OFFICER Date: 13/05/2022 POLY MEDICURE LTD. - 531768 - Board to consider FY22 results & Final Dividend on May 24, 2022
Poly Medicure Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 24, 2022, inter alia, to consider the following:1. To consider and approve the Audited Financial Results (Consolidated & Standalone) of the Company for the financial year ended on March 31, 2022.2. To consider recommendation of Final Dividend, if any, on the Equity Shares for the financial year ended on March 31. 2022.In continuation of the Company''s intimation regarding closure of trading window vide letter dated March 31, 2022, the Trading Window for dealing in securities of the Company shall remain closed till May 26, 2022. POLY MEDICURE LTD. - 531768 - Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On 24Th May, 2022
POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2022 ,inter alia, to consider and approve Dear Sir/Madam, Pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on Tuesday, the 24th May, 2022, inter alia to consider the following: a) To consider and approve the Audited Financial Results (Consolidated & Standalone) of the Company for the financial year ended on 31st March, 2022. b) To consider recommendation of Final Dividend, if any, on the Equity Shares for the financial year ended on 31st March, 2022. c) To transact any other matter which the Board may deem fit. In continuation of our intimation regarding closure of trading window vide letter dated 31st March, 2022, the Trading Window for dealing in securities of the Company shall remain closed till 26th May, 2022. This is for your information and record. Thanking You POLY MEDICURE LTD. - 531768 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayPOLY MEDICURE LTD. 2CINL40300DL1995PLC066923 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 30.56 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: AVINASH CHANDRA Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: cs@polymedicure.com Name of the Chief Financial Officer: NARESH VIJAYVERGIYA Designation: CHIEF FINANCIAL OFFICER EmailId: naresh.vijay@polymedicure.com Date: 30/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. POLY MEDICURE LTD. - 531768 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Polycure Martech Ltd POLY MEDICURE LTD. - 531768 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Polycure Martech Ltd & PACs